Minims Phenylephrine Chlorhydrate Bausch + Lomb Ireland Limited (Phenylephrine Hydrochloride)

Phenylephrine Hydrochloride is used in ophthalmology to produce mydriasis and to alleviate conjunctival hyperemia.

• Diagnostic mydriasis: provides rapid and reliable pupil dilation, enabling detailed fundus examination, retinal photography, and laser procedures.
• Ocular redness: reduces conjunctival hyperemia by vasoconstriction, improving comfort and cosmetic appearance in mild to moderate redness.
• Pre‑operative pupil dilation: facilitates intra‑ocular surgery by maintaining an adequately dilated pupil throughout the procedure.
• Anterior segment imaging: enhances visualization of corneal and anterior chamber structures for diagnostic imaging and assessment.

• Phenylephrine Hydrochloride acts as a selective alpha‑1 adrenergic receptor agonist on the dilator pupillae muscle and conjunctival vessels. Activation of these receptors causes smooth‑muscle contraction, leading to pupil dilation (mydriasis) and vasoconstriction of ocular surface vessels, which reduces redness. The effect is localized to the eye when administered as an ophthalmic solution. The localized action minimizes systemic absorption, although minimal systemic exposure can occur with excessive dosing.

Phenylephrine Hydrochloride ophthalmic solution may be associated with ocular and systemic adverse reactions.

Common Side Effects

• Stinging or burning sensation upon instillation.
• Transient blurred vision.
• Mild headache.
• Temporary increase in intra‑ocular pressure.

Serious or Rare Side Effects

• Severe allergic reaction (angio‑edema, anaphylaxis).
• Sustained mydriasis leading to photophobia.
• Acute angle‑closure glaucoma in predisposed eyes.
• Systemic hypertension or tachycardia after excessive absorption.

When using Phenylephrine Hydrochloride ophthalmic solution, several safety considerations should be observed.

• Allergy assessment: avoid if known hypersensitivity to phenylephrine or any excipients.
• Angle‑closure risk: use with caution in patients with narrow‑angle glaucoma or a history of angle‑closure events.
• Cardiovascular conditions: monitor patients with hypertension, coronary artery disease, or other cardiovascular disorders.
• Pregnancy and lactation: employ only if clearly indicated after professional evaluation.
• Concomitant ocular drugs: review other vasoconstrictors or mydriatics to prevent excessive effects.
• Store at room temperature: keep in the original container, protect from light and moisture.

Phenylephrine Hydrochloride may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): may potentiate systemic vasoconstriction and raise blood pressure.
• Other ocular sympathomimetics: risk of excessive mydriasis and ocular hypertension.

Moderate Interactions (Monitor Closely):\n- Systemic antihypertensives: phenylephrine may diminish their efficacy.

• Beta‑blockers: potential additive cardiovascular effects.
• Topical non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase ocular irritation.
• Anticholinergic eye drops: could alter pupil response dynamics.